Skip to main content
Top

Open Access 07-05-2025 | Spondyloarthropathy | ORIGINAL ARTICLE

Associations between comorbidities and patient-reported outcomes in axial spondyloarthritis: data from a single-center real-world cohort

Authors: Grzegorz Biedroń, Mateusz Wilk, Jarosław Nowakowski, Piotr Kuszmiersz, Zofia Guła, Magdalena Strach, Alen Brkic, Glenn Haugeberg, Mariusz Korkosz

Published in: Clinical Rheumatology

Login to get access

Abstract

Introduction

Comorbidities are frequently present in patients with axial spondyloarthritis (axSpA) and may contribute to poorer health-related outcomes. Patient-reported outcomes (PROs) serve as tools to assess the patient’s perspective on the burden of the disease. The study aimed to evaluating the impact of comorbidities on selected PROs in axSpA.

Method

Adult patients diagnosed with axSpA based on ASAS classification criteria were included in this cross-sectional study. Data collected included comorbidities and PROs [Health Assessment Questionnaire (HAQ), Multi-Dimensional Health Assessment Questionnaire (MDHAQ), 36-Item Short Form Health Survey (SF-36), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI)].

Results

In total, 323 participants were included in the study (44.0% female). Multimorbidity and extended multimorbidity were observed in 63.8% and 38.7% of patients, respectively. Extended multimorbidity was associated with higher HAQ (0.5 [0.1–1.0] vs. 0.3 [0.0–0.8], p < 0.01) and MDHAQ scores (0.3 [0.0–0.6] vs. 0.1 [0.0–0.5], p = 0.03). The BASDAI score was higher in patients with three or more comorbidities than in patients with no comorbidities (2.8 [1.7–4.3] vs. 1.9 [0.9–3.6], p < 0.01). The number of comorbidities was associated with higher scores in the mental health (β = 0.20, p < 0.01) and vitality (β = 0.16, p = 0.02) domains of the SF-36 questionnaire.

Conclusions

Multimorbidity was present in almost two-thirds of cases. Extended multimorbidity was associated with poorer physical functioning, HAQ, MDHAQ, and BASDAI scores, whereas multimorbidity was related to better scores in the mental health and vitality domains. The impact of comorbidities on PROs in axSpA should not be overlooked.
Key Points
Multimorbidity is frequent among axial spondyloarthritis’ patients.
Only extended multimorbidity (presence of two or more additional diseases, excluding axial spondyloarthritis) was found to be associated with poorer results of patient-reported outcomes, in particular these regarding physical functioning.
Multimorbidity might influence positively some domains of quality of life such as mental health or vitality.
The findings included in the study support the belief that in patients with spondyloarthritis comorbidities might impact patient-reported outcomes which are important when assessing disease activity and response to treatment and should not be disregarded.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Associations between comorbidities and patient-reported outcomes in axial spondyloarthritis: data from a single-center real-world cohort
Authors
Grzegorz Biedroń
Mateusz Wilk
Jarosław Nowakowski
Piotr Kuszmiersz
Zofia Guła
Magdalena Strach
Alen Brkic
Glenn Haugeberg
Mariusz Korkosz
Publication date
07-05-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-025-07452-6

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar